Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Venrock Healthcare Capital Par Acquires 58,054 Shares of Stock

Tricida, Inc. (NASDAQ:TCDAGet Rating) major shareholder Venrock Healthcare Capital Par purchased 58,054 shares of the company’s stock in a transaction dated Friday, June 10th. The shares were acquired at an average price of $8.91 per share, for a total transaction of $517,261.14. Following the purchase, the insider now directly owns 6,511,238 shares in the company, valued at $58,015,130.58. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

  • On Monday, June 13th, Venrock Healthcare Capital Par purchased 50,000 shares of Tricida stock. The shares were acquired at an average price of $8.14 per share, for a total transaction of $407,000.00.
  • On Wednesday, June 8th, Venrock Healthcare Capital Par purchased 111,111 shares of Tricida stock. The shares were acquired at an average price of $9.51 per share, for a total transaction of $1,056,665.61.
  • On Monday, June 6th, Venrock Healthcare Capital Par purchased 91,506 shares of Tricida stock. The shares were acquired at an average price of $9.35 per share, for a total transaction of $855,581.10.
  • On Thursday, June 2nd, Venrock Healthcare Capital Par purchased 61,722 shares of Tricida stock. The shares were acquired at an average price of $8.78 per share, for a total transaction of $541,919.16.

TCDA opened at $8.90 on Wednesday. The company has a debt-to-equity ratio of 584.92, a quick ratio of 5.12 and a current ratio of 5.12. Tricida, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $12.45. The firm’s fifty day moving average is $9.36 and its 200 day moving average is $9.04. The stock has a market cap of $493.28 million, a price-to-earnings ratio of -3.08 and a beta of 0.92.

Tricida (NASDAQ:TCDAGet Rating) last released its earnings results on Tuesday, March 29th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.21). During the same quarter in the prior year, the firm posted ($1.09) EPS. On average, equities research analysts predict that Tricida, Inc. will post -2.2 earnings per share for the current year.

A number of research analysts recently weighed in on TCDA shares. The Goldman Sachs Group lowered their target price on shares of Tricida from $22.00 to $16.00 and set a “buy” rating on the stock in a research note on Tuesday, May 24th. Needham & Company LLC restated a “buy” rating and set a $18.00 target price (down previously from $20.00) on shares of Tricida in a research note on Wednesday, March 30th.

Hedge funds have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Tricida by 92.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,270 shares of the company’s stock worth $27,000 after purchasing an additional 1,569 shares in the last quarter. Dorsey Wright & Associates purchased a new stake in Tricida in the 1st quarter worth $30,000. Quantbot Technologies LP purchased a new stake in Tricida in the 1st quarter worth $45,000. Royal Bank of Canada purchased a new stake in Tricida in the 1st quarter worth $55,000. Finally, Bank of America Corp DE lifted its stake in Tricida by 290.5% in the 1st quarter. Bank of America Corp DE now owns 7,400 shares of the company’s stock worth $61,000 after purchasing an additional 5,505 shares in the last quarter. Institutional investors and hedge funds own 79.28% of the company’s stock.

Tricida Company Profile (Get Rating)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Recommended Stories

Insider Buying and Selling by Quarter for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.